[1]Moser DJ, Hoth KF, Robinson RG, et al. Blood vessel function and cognition in elderly patients with atherosclerosis[J]. Stroke, 2004, 35(11): e369-e372.
[2]Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer′s disease in the Rotterdam Study[J]. Lancet, 1997, 349(9046): 151-154.
[3]McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease[J]. Exp Gerontol, 1998, 33(5): 371-378.
[4]Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25year followup of the HonoluluAsia Aging Study[J]. Ann Neurol, 2002, 52(2): 168-174.
[5]Yankner BA. Mechanisms of neuronal degeneration in Alzheimer′s disease[J]. Neuron, 1996, 16(5): 921-932.
[6]Kotani K, Serban MC, Penson P, et al. Evidencebased assessment of lipoprotein(a)as a risk biomarker for cardiovascular diseasessome answers and still many questions[J]. Crit Rev Clin Lab Sci, 2016, 53(6): 370-378.
[7]Breteler MM. Vascular risk factors for Alzheimer′s disease: an epidemiologic perspective[J]. Neurobiol Aging, 2000, 21(2): 153-160.
[8]丁彬彬,邬建民,介勇,等. 阿尔茨海默病和血管性痴呆患者血清炎症因子和生化指标的检测及临床意义[J]. 检验医学, 2016, 31(5): 363-367.
[9]余艳. 阿尔茨海默病早期认知功能障碍与血糖、血脂及炎性因子异常的相关性研究[J]. 沈阳医学院学报, 2019, 21(3): 204-206, 210.
[10]杨承芝,田金洲,钟剑.轻度认知损害和阿尔茨海默病患者的血脂变化[J]. 中国老年学杂志, 2007, 27(6):545-548.
[11]Iwamoto T, Watanabe D, Umahara T, et al. Dual inverse effects of lipoprotein(a)on the dementia process in Japanese lateonset Alzheimer′s disease[J]. Psychogeriatrics, 2004, 4(3): 64-71.
[12]Solfrizzi V, PanzaF, Introno AD, et al. Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer′s disease[J]. J Neurol Neurosurg Psychiatry, 2002, 72(6): 732-736.
[13]Mooser V, Helbecque N, Miklossy J, et al. Interactions between apolipoprotein E and apolipoprotein(a)in patients with lateonset Alzheimer disease[J]. Ann Intern Med, 2000, 132(7): 533-537.
[14]Kunutsor SK, Khan H, Nyyssnen K, et al. Is lipoprotein(a)protective of dementia?[J]. Eur J Epidemiol, 2016, 31(11): 1149-1152.
[15]Pokharel Y, Mouhanna F, Nambi V, et al. ApoB, smalldense LDLC, Lp(a), LpPLA2 activity, and cognitive change[J]. Neurology, 2019, 92(22): e2580-e2593.
[16]Sarti C, Pantoni L, Pracucci G, et al. Lipoprotein(a)and cognitive performances in an elderly white population: Crosssectional and followup data[J]. Stroke, 2001, 32(7): 1678-1683.
[17]Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications[J]. Lancet Neurol, 2019,18(7): 684-696.
[18]Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to bloodbrain barrier dysfunction predicting cognitive decline[J]. Nature, 2020, 581(7806): 71-76.
[19]Pepe G, Chimienti G, Liuzzi GM, et al. Lipoprotein(a) in the cerebrospinal fluid of neurological patients with bloodcerebrospinal fluid barrier dysfunction[J]. Clin Chem, 2006, 52(11): 2043-2048.
[20]Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies[J]. Nat Rev Neurol, 2019, 15(9): 501-518.
[21]Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDGPET[J]. Neurology, 2004,63(12): 2332-2340.
|